Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Tax Cuts Help Keep U.S. Companies Home -- WSJ

share with twitter share with LinkedIn share with facebook
share via e-mail
08/02/2019 | 02:48am EST

By Richard Rubin and Jared S. Hopkins

Inversions are starting to revert.

When Mylan moved its corporate address to the Netherlands in 2015, the pharmaceutical company joined a wave of corporate inversion deals aided by tax advantages of a non-U.S. address. Now, Mylan's address is coming back to the U.S. through a merger deal this week with part of Pfizer Inc., a sign that the 2017 tax law is rendering these moves less attractive than they once were.

The deal comes a month after Allergan PLC -- another inverted pharmaceutical company, based in Dublin -- announced its return to a U.S. parent through a sale to AbbVie Inc.

On balance, say tax lawyers and analysts, foreign addresses still confer a slight tax advantage.

But after the U.S. corporate tax cuts in the 2017 law, the edge is small enough that it might not be worth reputational and political costs.

Those changes might deter new inversions and cause inverted companies to retake U.S. addresses if other business reasons warrant such a move. Inversion deals were particularly hot from 2012 to 2015, as companies such as Eaton Corp. and Medtronic PLC took foreign addresses.

The moves generated political blowback as lawmakers criticized companies as abandoning the U.S. The dust-up led to new regulations and provided some of the impetus for the 2017 tax-code rewrite.

"Transactions that historically would have been structured as inversions are no longer being structured that way, even when the opportunity to do it is clearly there," said Robert Willens, a New York tax analyst. "Before, there was such a clear economic advantage to structuring as an inversion that you were willing to withstand the negative aspects."

Earlier this decade, companies had strong incentives to take non-U.S. addresses. U.S. companies owed the full 35% tax rate on their world-wide income, though they got credits for foreign taxes and deferred the U.S. layer until they repatriated money.

Foreign-based companies didn't face that second tax layer. And they could use a technique called earnings stripping, loading U.S. operations with deductible expenses and pushing profits into lower-taxed jurisdictions.

Through mergers, companies such as Allergan, Mylan, Medtronic and Johnson Controls PLC moved tax addresses abroad. The companies were often managed from the U.S.

"It was always a fiction that they were foreign," said Steve Wamhoff, director for federal tax policy at the Institute on Taxation and Economic Policy, a liberal group critical of corporate tax avoidance.

Obama administration regulations curbed some benefits. Then, the 2017 law cut the U.S. corporate tax rate to 21% from 35%, reducing incentives for profit shifting and using foreign-parented companies.

"The Trump administration's response to this whole situation was to cut corporate taxes enough that corporations don't really need to try that hard to avoid them," Mr. Wamhoff said.

The law also aimed at earnings stripping by adding a tax on certain cross-border transfers within companies.

"It's too early to say definitively that the playing field is level, but it is more level today than it was," said Bret Wells, a law professor at the University of Houston.

Because companies changed addresses without necessarily moving jobs or operations, inversions had limited economic effects. But the moves reduced federal revenue and disadvantaged U.S. companies competing against inverted firms.

In this week's deal, Pfizer's off-patent drug division will merge with Mylan, best known for the EpiPen emergency allergy treatment. The new, yet-unnamed company is expected to be among the biggest sellers of generic and off-patent medicines, with more than $19 billion in yearly sales.

Favorable corporate tax conditions resulting from the 2017 law contributed to the decision to domicile the new company in the U.S., according to people familiar with the merger. But an important reason was also Delaware's attractive corporate-governance rules for shareholders, according to Mylan and Pfizer.

"That's a very important part of the investment thesis," Albert Bourla, Pfizer's chief executive, said in an interview.

Analysts and investors had criticized Mylan's Dutch governance structure. Mylan's decision to become a Dutch corporation through an acquisition while keeping its headquarters in Pittsburgh was seen as defensive. Afterward, Mylan engaged in a takeover battle with rival Teva Pharmaceutical Industries Ltd. Mylan fended that off after setting up a foundation, called a stichting in Dutch, that triggered a Dutch variation on a poison pill.

Mylan's chairman, Robert J. Coury, told analysts this week that governance played a greater role than tax for Mylan's exit from the U.S. At the time of the inversion he endorsed inverting and its tax benefits in a USA Today commentary.

Allergan referred comment to AbbVie, which said in a written statement that remaining a U.S.-incorporated company was the most appropriate structure for the company.

Under the new tax system, there are still benefits to a non-U.S. address, because it can help companies avoid a new minimum tax on U.S. companies' foreign income. Also, the parent's address is only part of tax calculations. Some companies can still reduce U.S. taxes by reporting profits abroad or investing in foreign factories.

--Jonathan Rockoff contributed to this article.

Write to Richard Rubin at richard.rubin@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 0.77% 94.96 Delayed Quote.7.25%
ALLERGAN PLC 0.71% 200.15 Delayed Quote.4.70%
EATON CORPORATION PLC -0.16% 104.93 Delayed Quote.10.78%
MEDTRONIC PLC -0.51% 113.28 Delayed Quote.-0.15%
MYLAN N.V. 1.08% 21.15 Delayed Quote.5.22%
PFIZER -0.36% 35.72 Delayed Quote.-8.83%
PFIZER LIMITED -0.77% 4187.55 End-of-day quote.-0.88%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
05:42aEXCLUSIVE : Germany's Stada buys 15 GSK consumer health brands
RE
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/19PFIZER INC. : - European Commission Approves VYNDAQEL, the First Treatment in th..
AQ
02/18PFIZER : Gets European Approval for Vyndaqel in ATTR-CM
DJ
02/18PFIZER : European Commission Approves VYNDAQEL®, the First Treatment in the EU f..
BU
02/14Sosei Heptares Operational Highlights and Consolidated Results for the 12 Mon..
AQ
02/13Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides Inc
AQ
02/12ASTELLAS PHARMA : XTANDI Demonstrates Significant Improvement in Overall Surviva..
AQ
02/11PFIZER : XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall ..
PR
02/10Lilly, Roche Drugs Fail to Halt Inherited Form of Alzheimer's -- 2nd Update
DJ
More news
Financials (USD)
Sales 2020 46 032 M
EBIT 2020 17 998 M
Net income 2020 12 525 M
Debt 2020 24 296 M
Yield 2020 4,16%
P/E ratio 2020 18,4x
P/E ratio 2021 17,7x
EV / Sales2020 4,82x
EV / Sales2021 4,68x
Capitalization 198 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 43,87  $
Last Close Price 35,72  $
Spread / Highest target 54,0%
Spread / Average Target 22,8%
Spread / Lowest Target 3,58%
EPS Revisions
Managers
NameTitle
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Mikael Dolsten Chief Scientific Officer
Lidia L. Fonseca Chief Technology Officer & EVP
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-8.83%197 679
JOHNSON & JOHNSON2.78%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
NOVO NORDISK AS14.48%149 779